5th Complement-based

5th Complement-based image 1
Contacte al anunciante
(617) 455-4188
Contacte al anunciante

Built with Alexion, Apellis and Annexon, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industrydedicated forum to maximize complement-targeting in the pan-disease setting.

With pivotal clinical readouts poised to be released in 2021, this year's summit will once again unite thought leaders in complement-based drug development.

Expect to be involved in interactive discussions on:

- How dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5
- Preclinical and clinical pipeline progress of diverse drug modalities, including gene therapy approaches, small molecule inhibitors, antibodies, protease inhibitors, nucleic acids and more!
- Leveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics
- Addressing clinical challenges of complement-targeted therapeutic sequencing, combinations and timing of administration
- Expanding the clinical utility of complement inhibitors across rare diseases, as well as autoimmune, ophthalmic, neurological and cancer settings

New for this year, you'll have a two-tracked agenda with more speakers, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets!

Running digitally October 26-28, 2021.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Date and Time: On Tuesday October 26, 2021 at 1:00 pm (ends Thursday October 28, 2021 at 5:00 pm)

Prices:

Conference + 1 Workshop (DRUG DEVELOPER PRICING): USD 2498.00,
Conference Only (DRUG DEVELOPER PRICING): USD 2099.00,
Conference + 1 Workshop (ACADEMIC PRICING): USD 1698.00,
Conference Only (ACADEMIC PRICING): USD 1399.00,
Conference + 1 Workshop (INDUSTRY PRICING): USD 3298.00,
Conference Only (INDUSTRY PRICING): USD 2799.00

URLs:

Tickets: https://go.evvnt.com/805196-1?pid=6842

Brochure: https://go.evvnt.com/805196-3?pid=6842

Venue details: Online

Speakers: Tim Higenbottam, Professor, Akari Therapeutics, Anita Hill, Vice President, Global Medical Affairs Lead Haematology and Nephrology, Consultant Clinical Development, Alexion, Moshe Vardi, VP, R&D Global Medicine Team Leader Hematology/Nephrology, Alexion, Shamsah Kazani, Sr. Medical Director Hematology/Nephrology, Alexion, Sanjay Keswani, EVP and Chief Medical Officer, Annexon Biosciences, Lukas Scheibler, Chief Innovation Officer, Apellis, Inge Van de Walle, Principal Scientist, argenx, Yingying Zhang, Postdoctoral Fellow, Boston Children’s Hospital (Michael Carroll’s lab) and more

Built with Alexion, Apellis and Annexon, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industrydedicated forum to maximize complement-targeting in the pan-disease setting.

With pivotal clinical readouts poised to be released in 2021, this year's summit will once again unite thought leaders in complement-based drug development.

Expect to be involved in interactive discussions on:

- How dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5
- Preclinical and clinical pipeline progress of diverse drug modalities, including gene therapy approaches, small molecule inhibitors, antibodies, protease inhibitors, nucleic acids and more!
- Leveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics
- Addressing clinical challenges of complement-targeted therapeutic sequencing, combinations and timing of administration
- Expanding the clinical utility of complement inhibitors across rare diseases, as well as autoimmune, ophthalmic, neurological and cancer settings

New for this year, you'll have a two-tracked agenda with more speakers, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets!

Running digitally October 26-28, 2021.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Date and Time: On Tuesday October 26, 2021 at 1:00 pm (ends Thursday October 28, 2021 at 5:00 pm)

Prices:

Conference + 1 Workshop (DRUG DEVELOPER PRICING): USD 2498.00,
Conference Only (DRUG DEVELOPER PRICING): USD 2099.00,
Conference + 1 Workshop (ACADEMIC PRICING): USD 1698.00,
Conference Only (ACADEMIC PRICING): USD 1399.00,
Conference + 1 Workshop (INDUSTRY PRICING): USD 3298.00,
Conference Only (INDUSTRY PRICING): USD 2799.00

URLs:

Tickets: https://go.evvnt.com/805196-1?pid=6842

Brochure: https://go.evvnt.com/805196-3?pid=6842

Venue details: Online

Speakers: Tim Higenbottam, Professor, Akari Therapeutics, Anita Hill, Vice President, Global Medical Affairs Lead Haematology and Nephrology, Consultant Clinical Development, Alexion, Moshe Vardi, VP, R&D Global Medicine Team Leader Hematology/Nephrology, Alexion, Shamsah Kazani, Sr. Medical Director Hematology/Nephrology, Alexion, Sanjay Keswani, EVP and Chief Medical Officer, Annexon Biosciences, Lukas Scheibler, Chief Innovation Officer, Apellis, Inge Van de Walle, Principal Scientist, argenx, Yingying Zhang, Postdoctoral Fellow, Boston Children’s Hospital (Michael Carroll’s lab) and more

Contacte al anunciante